Skip to main content
. 2019 Dec 9;29:100976. doi: 10.1016/j.rmcr.2019.100976

Fig. 5.

Fig. 5

(A) Computed tomography (CT) images after six courses of pembrolizumab showing enlargement of squamous cell carcinoma in the right middle lobe and no change in adenocarcinoma in the lower lobe, compared with pretreatment images.

(B) CT images after two courses with TS-1 therapy as second-line chemotherapy showing reductions in the size of both tumors.